UBS AM’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-4,788
| Closed | -$567K | – | 2821 |
|
|
2021
Q1 | $567K | Sell |
4,788
-1,490
| -24% | -$176K | ﹤0.01% | 2342 |
|
|
2020
Q4 | $741K | Hold |
6,278
| – | – | ﹤0.01% | 2129 |
|
|
2020
Q3 | $698K | Buy |
6,278
+2,708
| +76% | +$291K | ﹤0.01% | 1983 |
|
|
2020
Q2 | $365K | Hold |
3,570
| – | – | ﹤0.01% | 2233 |
|
|
2020
Q1 | $385K | Hold |
3,570
| – | – | ﹤0.01% | 2074 |
|
|
2019
Q4 | $415K | Sell |
3,570
-5,271
| -60% | -$610K | ﹤0.01% | 2297 |
|
|
2019
Q3 | $1.01M | Buy |
8,841
+4,902
| +124% | +$487K | ﹤0.01% | 1945 |
|
|
2019
Q2 | $375K | Sell |
3,939
-29,331
| -88% | -$2.76M | ﹤0.01% | 2330 |
|
|
2019
Q1 | $3.04M | Sell |
33,270
-177,454
| -84% | -$14.5M | ﹤0.01% | 1339 |
|
|
2018
Q4 | $16M | Buy |
210,724
+5,300
| +3% | +$390K | 0.01% | 754 |
|
|
2018
Q3 | $16.4M | Buy |
+205,424
| New | +$19.1M | 0.01% | 812 |
|
|
2017
Q3 | – | Sell |
-225,140
| Closed | -$25.5M | – | 2587 |
|
|
2017
Q2 | $25.5M | Buy |
225,140
+26,920
| +14% | +$3.01M | 0.02% | 656 |
|
|
2017
Q1 | $19.8M | Buy |
198,220
+16,933
| +9% | +$1.81M | 0.02% | 719 |
|
|
2016
Q4 | $19.5M | Buy |
181,287
+3,217
| +2% | +$376K | 0.02% | 692 |
|
|
2016
Q3 | $22.2M | Sell |
178,070
-23,195
| -12% | -$2.74M | 0.02% | 644 |
|
|
2016
Q2 | $21.4M | Buy |
201,265
+6,509
| +3% | +$756K | 0.02% | 649 |
|
|
2016
Q1 | $22.3M | Buy |
194,756
+3,977
| +2% | +$467K | 0.03% | 622 |
|
|
2015
Q4 | $27.2M | Sell |
190,779
-231
| -0.1% | -$26.7K | 0.03% | 546 |
|
|
2015
Q3 | $17.2M | Buy |
191,010
+29,381
| +18% | +$3.1M | 0.02% | 724 |
|
|
2015
Q2 | $18.6M | Buy |
+161,629
| New | +$17M | 0.02% | 739 |
|
UBS AM's CBPO Position: Q2 2021 in Review
UBS AM sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 4,788 shares — an estimated $567K sold.
UBS AM first reported a position in CBPO in Q2 2015 and held it in 20 quarters. The position peaked at $27.2M in Q4 2015. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- UBS AM reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- UBS AM sold 4,788 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $567K.
- UBS AM first reported a position in China Biologic Products Holdings, Inc. in Q2 2015 and held it in 20 quarters.
- UBS AM's China Biologic Products Holdings, Inc. position peaked at $27.2M in Q4 2015.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.